Subclinical disease revisited.

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Adjuvant radiotherapy is standard for improving local control in postoperative patients.
• The concept of "subclinical disease" assumes residual microscopic tumor cells necessitate adjuvant therapy.
• Positive or close surgical margins and lymph node involvement are typical indications for adjuvant treatment.

Purpose of the Study:

• To critically evaluate recent evidence that questions the universal need for adjuvant therapy in cases of presumed subclinical disease.
• To reassess the fundamental assumption that all residual disease inevitably leads to local failure without adjuvant treatment.

Main Methods:

• Literature review of recent reports and studies.
• Critical analysis of existing assumptions regarding subclinical disease and adjuvant therapy.
• Discussion of findings that challenge established treatment paradigms.

Main Results:

• Emerging evidence suggests that not all patients with microscopic residual disease experience local failure if left untreated.
• The interpretation of "close" or "microscopically positive" margins may require re-evaluation.
• The absolute indication for adjuvant therapy based solely on these findings is being questioned.

Conclusions:

• The assumption that all subclinical disease requires adjuvant treatment may not hold true for all head and neck cancer patients.
• Further research is needed to refine indications for adjuvant therapy, potentially sparing some patients from radiotherapy.
• Personalized treatment strategies may be developed based on a more nuanced understanding of residual disease risk.